Development and validation of a fast ultra-high-performance liquid chromatography tandem mass spectrometry method for determining carbonic anhydrase inhibitors and their metabolites in urine and hair.


Journal

Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449

Informations de publication

Date de publication:
Aug 2021
Historique:
revised: 12 04 2021
received: 17 03 2021
accepted: 23 04 2021
pubmed: 29 4 2021
medline: 13 1 2022
entrez: 28 4 2021
Statut: ppublish

Résumé

A new, rapid, sensitive, and comprehensive ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for quantifying diuretics (acetazolamide, brinzolamide, dorzolamide, and their metabolites) in human urine and hair was developed and fully validated. Twenty-five milligrams of hair were incubated with 500-μl M3® buffer reagent at 100°C for 1 h for complete digestion. After cooling, 1-μl supernatant was injected onto chromatography system. Urine samples were simply diluted before injection. The chromatographic run time was short (8 min) through a column with a mobile phase gradient. The method was linear (determination coefficients always higher than 0.99) from limit of quantification (LOQ) to 500 ng/ml in urine and from LOQ to 10 ng/mg in hair. LOQs ranged from 0.07 to 1.16 ng/ml in urine and from 0.02 to 0.15 ng/mg in hair. No significant ion suppression due to matrix effect was observed, and process efficiency was always higher than 80%. Intra- and inter-assay precision was lower than 15%. The suitability of the methods was tested with six urine and hair specimens from patients treated with acetazolamide, dorzolamide, or brinzolamide for ocular diseases or systemic hypertension. Average urine concentrations were 266.32 ng/ml for dorzolamide and 47.61 ng/ml for N-deethyl-dorzolamide (n = 3), 109.27 ng/ml for brinzolamide and 1.02 ng/ml for O-desmethyl-brinzolamide (n = 2), and finally, 12.63 ng/ml for acetazolamide. Average hair concentrations were 5.94 ng/mg for dorzolamide and 0.048 ng/mg for N-deethyl-dorzolamide (n = 3), 3.26 ng/mg for brinzolamide (n = 2), and 2.3 ng/mg for acetazolamide (n = 1). The developed method was simple and fast both in the extraction procedures making it eligible in high-throughput analysis for clinical forensic and doping purposes.

Identifiants

pubmed: 33908166
doi: 10.1002/dta.3055
pmc: PMC8456811
doi:

Substances chimiques

Carbonic Anhydrase Inhibitors 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1552-1560

Subventions

Organisme : Antidoping Commission, Ministry of Health

Informations de copyright

© 2021 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.

Références

Am J Ophthalmol. 1968 Oct;66(4):680-3
pubmed: 5729585
Br J Pharmacol. 2010 Sep;161(1):1-16
pubmed: 20718736
Drug Test Anal. 2021 Aug;13(8):1552-1560
pubmed: 33908166
Expert Opin Drug Deliv. 2010 Aug;7(8):943-53
pubmed: 20565335
Drug Res (Stuttg). 2014 Sep;64(9):499-504
pubmed: 24443308
J Pharm Biomed Anal. 2002 Apr 15;28(2):391-7
pubmed: 11929684
Am J Med Sci. 2000 Jan;319(1):38-50
pubmed: 10653443
J Chromatogr. 1991 Feb 15;563(2):257-70
pubmed: 2055991
J Pharm Anal. 2020 Feb;10(1):49-59
pubmed: 32123599
Curr Pharm Des. 2017;23(36):5442-5454
pubmed: 28714407
J Chromatogr A. 2006 Dec 1;1135(2):219-29
pubmed: 17027009
J Pharm Biomed Anal. 2016 Feb 5;119:84-90
pubmed: 26669612
Semin Nephrol. 2011 Nov;31(6):495-502
pubmed: 22099506
J Anal Toxicol. 2013 Sep;37(7):452-74
pubmed: 23934984
Anal Chem. 2003 Jul 1;75(13):3019-30
pubmed: 12964746
Ther Drug Monit. 2005 Aug;27(4):509-20
pubmed: 16044110
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1248-1257
pubmed: 30936153
Ann Clin Biochem. 2012 Sep;49(Pt 5):419-31
pubmed: 22783025
J Pharm Biomed Anal. 2010 May 1;52(1):142-8
pubmed: 20053517
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 1;1022:109-117
pubmed: 27085020
Curr Pharm Des. 2017;23(36):5455-5467
pubmed: 28641530
J Pharm Biomed Anal. 1997 Apr;15(7):1001-8
pubmed: 9160268

Auteurs

Alfredo Fabrizio Lo Faro (AF)

Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Ancona, Italy.

Anastasio Tini (A)

Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Ancona, Italy.

Massimo Gottardi (M)

Comedical s.r.l., Trento, Italy.

Filippo Pirani (F)

Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Ancona, Italy.

Ascanio Sirignano (A)

School of Law, University of Camerino, Camerino, Italy.

Raffaele Giorgetti (R)

Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Ancona, Italy.

Francesco Paolo Busardò (FP)

Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Ancona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH